Related Experiment Video
Updated: Jun 3, 2026
06:29
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
Published on: January 29, 2014
[Atypical hemolytic-uremic syndrome related to abnormalities within the complement system]
V Frémeaux-Bacchi1, F Fakhouri, L Roumenina
1Service d'immunologie biologique, hôpital Européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20-40, rue Leblanc, 75908 Paris cedex 15, France. veronique.fremeaux-bacchi@egp.aphp.fr
La Revue De Medecine Interne
|March 8, 2011
Summary
Atypical hemolytic uremic syndrome (aHUS) is a genetic disorder affecting complement pathways, often triggered by infections or pregnancy. Genetic testing identifies predisposition, guiding potential new treatments for this severe kidney disease.
Area of Science:
- Nephrology
- Immunology
- Genetics
Background:
- Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by hemolytic anemia, thrombocytopenia, and acute kidney injury.
- Atypical HUS (aHUS) forms, unrelated to Shiga toxin, can be familial or sporadic, often leading to end-stage renal failure and relapses.
- Genetic predisposition to aHUS involves complement alternative pathway genes, including CFH, CD46, CFI, C3, and CFB.
Purpose of the Study:
- To review the genetic basis of atypical hemolytic uremic syndrome (aHUS).
- To discuss the role of complement system dysregulation in aHUS pathogenesis.
- To highlight the clinical implications, prognosis, and emerging therapeutic strategies for aHUS.
Main Methods:
- Review of scientific literature on genetic factors and complement pathways in atypical HUS.
- Analysis of clinical data regarding disease manifestation, triggers, and outcomes.
- Discussion of diagnostic approaches, including molecular genetic testing.
Main Results:
- Genetic variations in complement regulatory proteins (CFH, CD46, CFI, C3, CFB) confer predisposition to aHUS.
- Incomplete penetrance means mutations predispose, but a second event (genetic/environmental) is needed for disease onset.
- Uncontrolled complement activation leads to endothelial damage and a prothrombotic state, with severe outcomes including high mortality and dialysis rates.
Conclusions:
- Understanding genetic susceptibility factors for aHUS is crucial for diagnosis and management.
- Atypical HUS has a severe prognosis, with high recurrence risk post-transplant and variable response to plasma therapy.
- Advances in genetic testing pave the way for targeted therapies, such as complement inhibitors.
More Related Videos
Related Concept Videos
01:27Complement System
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
01:19Hypersensitivity Reactions: Immune-Complex Reactions
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
01:01Hypersensitivity Reactions: Cytolytic Reactions
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
01:36Humoral Immune Responses
Overview
02:45Blood Transfusion and Agglutination
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...